Alternative Data for Astria Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 10,993 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Astria Therapeutics
None
| Price | $12.58 |
| Target Price | Sign up |
| Volume | 3,110,000 |
| Market Cap | $718M |
| Year Range | $5.43 - $13.2 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
BioCryst Pharma (BCRX) Subject to Prise Target Raise by WedbushMarch 10 - Yahoo Entertainment |
|
 |
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That”February 6 - Yahoo Entertainment |
 |
BioCryst: A Changed And Interesting Thesis For 2026January 19 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 710,000 | 0 | 0 | -32M | -32M | -0.550 |
| Q2 '25 | 0 | 0 | 0 | -33M | -36M | -0.570 |
| Q1 '25 | 0 | 0 | 0 | -34M | -37M | -0.580 |
| Q4 '24 | 0 | 0 | 0 | -26M | -30M | -0.440 |
| Q3 '24 | 0 | 0 | 0 | -25M | -29M | -0.420 |
Insider Transactions View All
| EDELMAN JOSEPH filed to buy 4,873,721 shares at $12.1. February 5 '24 |
| EDELMAN JOSEPH filed to buy 2,392,371 shares at $6.2. December 22 '23 |
Similar companies
Read more about Astria Therapeutics (ATXS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Astria Therapeutics
The Market Cap of Astria Therapeutics is $718M.
Currently, the price of one share of Astria Therapeutics stock is $12.58.
The ATXS stock price chart above provides a comprehensive visual representation of Astria Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Astria Therapeutics shares. Our platform offers an up-to-date ATXS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Astria Therapeutics (ATXS) does not offer dividends to its shareholders. Investors interested in Astria Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Astria Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
